Search clinical trials for: bimatoprost ophthalmic solution formulation A

Total 2280 results

Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Idiopathic Eyelash Hypotrichosis

Russian Federation, Sweden, United States, United Kingdom
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Alopecia | Baldness

United States, Germany
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States, Germany
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Terminated

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Glaucoma

United Kingdom, Taiwan, Korea, Republic of, United States, Italy, Philippines, France
Allergan

Completed

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Allergan

Completed

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Androgenetic Alopecia

United States
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, Czech Republic, Germany, Russian Federation, Hungary, Australia, Israel, United Kingdom, United States
Singapore National Eye Centre
Allergan

Unknown

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

Glaucoma, Angle-Closure

Singapore
Allergan

Completed

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Alopecia | Alopecia, Androgenetic | Baldness

United States
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Breast Cancer | Alopecia

United States
Tulane University
Allergan

Completed

Topical Bimatoprost for Chemical Blepharoplasty

Dermatochalasis

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Alopecia Areata | Eyelash Hypotrichosis

United States, Brazil
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (XLT)

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Allergan

Completed

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Hypotrichosis

United States
University of California, San Francisco

Completed

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Alopecia Areata

United States
Assiut University

Unknown

Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo

Generalized Vitiligo
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Laboratoires Thea

Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Healthy Volunteers

United States
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Allergan

Completed

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Laboratoires Thea

Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension | Glaucoma

United States, Colombia
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Allergan

Completed

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Innovative Medical

Completed

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Glaucoma

United States
Allergan

Completed

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

Evaluation of Safety and Tolerability of Ocular Lubricants

Dry Eye

Australia
Alcon Research

Completed

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Ocular Hypertension | Glaucoma
Julie Dawson

Completed

RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. (CMO)

Open Angle Glaucoma and Cataract

United Kingdom
Allergan

Completed

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

Dry Eye Syndromes

United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Alopecia | Alopecia, Androgenetic | Baldness

United States

3

Subscribe